Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis.

Advanced Localized Meta-analysis Prostate cancer Vasectomy

Journal

European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568

Informations de publication

Date de publication:
Jul 2022
Historique:
accepted: 27 04 2022
entrez: 31 5 2022
pubmed: 1 6 2022
medline: 1 6 2022
Statut: epublish

Résumé

Previous reports have shown an association between vasectomy and prostate cancer (PCa). However, there exist significant discrepancies between studies and systematic reviews due to a lack of strong causal association and residual confounding factors such as prostate-specific antigen (PSA) screening. To assess the association between vasectomy and PCa, in both unadjusted and PSA screen-adjusted studies. We performed a systematic review according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The PubMed, Scopus, and Web of Science databases were searched in January 2022 for studies that analyzed the association between vasectomy and PCa. A total of 37 studies including 16 931 805 patients met our inclusion criteria. A pooled analysis from all studies showed a significant association between vasectomy and any-grade PCa (odds ratio [OR] 1.23; 95% confidence interval [CI], 1.10-1.37; Our meta-analysis found an association between vasectomy and any, mainly localized, PCa. However, the effect estimates of the association were increasingly close to null when examining studies of robust design and high quality. On exploratory analyses including studies, which adjusted for PSA screening, the association for aggressive and/or advanced PCa diminished. In this study, we found an association between vasectomy and the risk of developing localized prostate cancer without being able to determine whether the procedure leads to a higher prostate cancer incidence.

Identifiants

pubmed: 35633829
doi: 10.1016/j.euros.2022.04.012
pii: S2666-1683(22)00587-0
pmc: PMC9130083
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

35-44

Informations de copyright

© 2022 The Author(s).

Références

J Clin Oncol. 2016 Nov 10;34(32):3880-3885
pubmed: 27646949
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
J Clin Oncol. 2014 Sep 20;32(27):3033-8
pubmed: 25002716
JAMA Oncol. 2017 May 1;3(5):705-707
pubmed: 28033446
JAMA. 2002 Jun 19;287(23):3110-5
pubmed: 12069674
BMJ. 2016 Nov 3;355:i5546
pubmed: 27811008
J Clin Oncol. 2016 Dec 20;34(36):4338-4344
pubmed: 27998216
Asian Pac J Cancer Prev. 2005 Jul-Sep;6(3):320-5
pubmed: 16235993
Cancer Causes Control. 2010 Jan;21(1):117-25
pubmed: 19816779
Cancer Epidemiol. 2020 Feb;64:101631
pubmed: 31760357
Cancer Epidemiol Biomarkers Prev. 1999 Oct;8(10):881-6
pubmed: 10548316
JAMA Intern Med. 2017 Sep 1;177(9):1273-1286
pubmed: 28715534
Stud Fam Plann. 1990 Jan-Feb;21(1):51-4
pubmed: 2180135
Cancer Causes Control. 2005 Apr;16(3):263-73
pubmed: 15947878
Andrology. 2015 Jul;3(4):643-9
pubmed: 26041315
Contraception. 2009 May;79(5):363-8
pubmed: 19341848
J Urol. 2008 Dec;180(6):2565-7; discussion 2567-8
pubmed: 18930503
Fertil Steril. 2005 Nov;84(5):1438-43
pubmed: 16275241
Prostate Cancer Prostatic Dis. 1997 Dec;1(2):73-78
pubmed: 12496919
JAMA. 1993 Feb 17;269(7):878-82
pubmed: 8123059
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):962-975
pubmed: 33927357
J Natl Cancer Inst. 1995 May 3;87(9):662-9
pubmed: 7538594
Can J Urol. 2011 Dec;18(6):6018-24
pubmed: 22166329
JAMA. 1993 Feb 17;269(7):873-7
pubmed: 8426446
Cancers (Basel). 2020 Aug 15;12(8):
pubmed: 32824199
Int Braz J Urol. 2012 Nov-Dec;38(6):769-78
pubmed: 23302414
Ann Epidemiol. 2004 Oct;14(9):655-62
pubmed: 15380796
J Urol. 1999 Jun;161(6):1848-52; discussion 1852-3
pubmed: 10332451
J Urol. 2002 Aug;168(2):488-90
pubmed: 12131294
Cancer Epidemiol Biomarkers Prev. 2017 Nov;26(11):1653-1659
pubmed: 28830873
Cancer Causes Control. 2005 Dec;16(10):1189-94
pubmed: 16215869
J Urol. 2015 May;193(5):1596-601
pubmed: 25463997
Andrology. 2019 Mar;7(2):178-183
pubmed: 30714352
Contraception. 2018 Jan;97(1):14-21
pubmed: 29038071
Am J Epidemiol. 1994 Sep 1;140(5):431-8
pubmed: 8067335
J Clin Oncol. 2017 Apr 20;35(12):1297-1303
pubmed: 28375714
J Natl Cancer Inst. 2020 Jan 1;112(1):71-77
pubmed: 31119294
Cancer Causes Control. 1994 Jan;5(1):66-72
pubmed: 7510134
J Urol. 2018 Jul;200(1):121-125
pubmed: 29524505
Int J Cancer. 2017 Feb 1;140(3):565-574
pubmed: 27741552
Am J Epidemiol. 1990 Dec;132(6):1056-61; discussion 1062-5
pubmed: 2260537
Health Place. 2001 Jun;7(2):131-9
pubmed: 11470226
Cell Biol Int. 2006 Feb;30(2):169-74
pubmed: 16360325
Am J Epidemiol. 1993 Feb 1;137(3):263-9
pubmed: 8452134
Carcinogenesis. 2021 Feb 11;42(1):31-37
pubmed: 32772072
Urol Oncol. 2017 Nov;35(11):663.e1-663.e7
pubmed: 28736250
Prostate Cancer. 2013;2013:682750
pubmed: 23533778
Int J Epidemiol. 1997 Oct;26(5):933-8
pubmed: 9363512
J Urol. 2012 Dec;188(6 Suppl):2482-91
pubmed: 23098786
Lancet Glob Health. 2015 Dec;3(12):e733-4
pubmed: 26545447
Prostate Cancer Prostatic Dis. 2021 Dec;24(4):939-941
pubmed: 34108643
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120

Auteurs

Michael Baboudjian (M)

Department of Urology, APHM, North Academic Hospital, Marseille, France.
Department of Urology, Fundació Puigvert, Autonoma University of Barcelona, Barcelona, Spain.
Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.
IUCT-O, Toulouse, France.

Pawel Rajwa (P)

Department of Urology, Medical University of Vienna, Vienna, Austria.
Department of Urology, Medical University of Silesia, Zabrze, Poland.

Eric Barret (E)

Department of Urology, Institut Mutualiste Montsouris, Paris, France.

Jean-Baptiste Beauval (JB)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.
IUCT-O, Toulouse, France.

Laurent Brureau (L)

Department of Urology, CHU de Pointe-à-Pitre, University of Antilles, University of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Pointe-à-Pitre, France.

Gilles Créhange (G)

Department of Radiotherapy, Institut Curie, Paris, France.

Charles Dariane (C)

Department of Urology, Hôpital Européen Georges-Pompidou, APHP, Paris - Paris University - U1151 Inserm-INEM, Necker, Paris, France.

Gaëlle Fiard (G)

Department of Urology, Grenoble Alpes University Hospital, Université Grenoble Alpes, CNRS, Grenoble INP, TIMC-IMAG, Grenoble, France.

Gaëlle Fromont (G)

Department of Pathology, CHRU Tours, Tours, France.

Mathieu Gauthé (M)

Department of Nuclear Medicine, Scintep - Institut Daniel Hollard, Grenoble, France.

Romain Mathieu (R)

Department of Urology, CHU Rennes, Rennes, France.

Raphaële Renard-Penna (R)

AP-HP, Radiology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.

Guilhem Roubaud (G)

Department of Medical Oncology, Institut Bergonié, Bordeaux, France.

Alain Ruffion (A)

Service d'urologie Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, Lyon, France.
Equipe 2, Centre d'Innovation en cancérologie de Lyon (EA 3738 CICLY), Faculté de médecine Lyon Sud, Université Lyon 1, Lyon, France.

Paul Sargos (P)

Department of Radiotherapy, Institut Bergonié, Bordeaux, France.

Morgan Rouprêt (M)

GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.

Guillaume Ploussard (G)

Department of Urology, La Croix du Sud Hôpital, Quint Fonsegrives, France.
IUCT-O, Toulouse, France.
Department of Urology, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.

Classifications MeSH